Oral anti-CD3 monoclonal antibody delays diabetes in non-obese diabetic (NOD) mice: Effects on pregnancy and offspring-a preliminary report

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 5, 2011, Pages 480-487

  Bevier, Wendy C ^a   Trujillo, Angelina L ^a   Primbs, George B ^a   Bradley, Maia K ^a   Jovanovič, Lois ^a  

^a SANSUM DIABETES RESEARCH INSTITUTE   (United States)

Author keywords

Anti CD3 monoclonal antibody; NOD mouse; Pregnancy

Indexed keywords

GLUCOSE; MONOCLONAL ANTIBODY CD3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; LONGEVITY; MALE; MOUSE; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROGENY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNE TOLERANCE; MALE; MICE; MICE, INBRED NOD; PILOT PROJECTS; PREGNANCY;

EID: 79960171394     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1204     Document Type: Article

References (30)

1. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986; 314: 1360-1368.
2. Lambert AP, Gillespie KM, Thomson G, et al. Absolute risk of childhood-onset T1DM defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. J Clin Endocrinol Metab 2004; 89: 4037-4043.
3. Raz I, Eldor R, Naparstek Y. Immune modulation for prevention of T1DM mellitus. Trends Biotechnol 2005; 23: 128-134.
4. Maier LM, Wicker LS. Genetic susceptibility to T1DM. Curr Opin Immunol 2005; 17: 601-608.
5. Lammi N, Karvonen M, Tuomilehto J. Do microbes have a causal role in T1DM? Med Sci Monit 2005; 11: RA63-RA69.
6. Daneman D. T1DM. Lancet 2006; 367: 847-858.
7. Rewers M, Barriga K, Baxter J, Eisenbarth G, Gesualdo P, Hoffman M, Ide L, Norris J, Waugh K, Simell OG, Nanto-Salonen K, Ilonen J, Knip M, Veijola R, Simell T, Hyöty H, Virtanen SM, Kronberg-Kippilä C, Torma M, Simmell B, Ruohonen E, Romo M, Mantymaki E, Niininen T, Nyblom M, Stenius A, Lernmark A, Agardh D, Almgren P, Andersson-Turpeinen M, Andrén-Aronsson C, Ask M, Carlsson UM, Cilio C, Bremer J, Ericson-Hallström E, Gerardsson J, Gustavsson B, Hansson G, Hansson I, Hansen M, Hyberg S, Håkansson R, Ivarsson S, Johansoon J, Larsson H, Lernmark B, Markan M, Melin J, Månsson-Martinez M, Nilsson A, Rahmati K, Järvirova MS, Sjöberg B, Törn C, Wallin A, Wigheden I, Wimar A, Hagopian WA, Hui P, Brantley M, Crouch CC, Hay KM, Ayres S, Hammar C, Steptikova V, Skidmore J, Bang B, Mulenga D, Vanneman N, Ewing J, Whitaker I, Wion E, Arrecis E, Trope L, Becker D, Franciscus M, Dalmagro-Elias M, Daftary A, Krischer JP, Abbondondolo M, Ballard L, Bounmananh L, Brown R, Cuthbertson D, Foster C, Gowda V, Lee HS, Liu S, Malloy J, McCarthy C, McLeod W, Nallamshetty L, Smith S, Uusitalo U, Vehik K, Yang J, Akolkar B, Briese T, Erlich H, Johnson SB (The Environmental Determinants of Diabetes in the Young (TEDDY) study). Ann N Y Acad Sci 2008; 1150: 1-13.
8. Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of T1DM in NOD mice. Nature 2005; 435: 220-223.
9. Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435: 224-228.
10. von Herrath M, Sanda S, Herold K. T1DM as a relapsing-remitting disease? Nat Rev Immunol 2007; 7: 988-994.
11. Shoda LK, Young DL, Ramanujan S, et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 2005; 23: 115-126.
12. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of T1DM: human trials and a look into the future. Diabetes Care 2009; 32: 1769-1782.
13. Fandrich F, Ungefroren H. Customized cell-based treatment options to combat autoimmunity and restore beta-cell function in T1DM mellitus: current protocols and future perspectives. Adv Exp Med Biol 2010; 654: 641-665.
14. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997; 158: 2947-2954.
15. Mottram PL, Murray-Segal LJ, Han W, Maguire J, Stein-Oakley AN. Remission and pancreas isograft survival in recent onset diabetic NOD mice after treatment with low-dose anti-CD3 monoclonal antibodies. Transpl Immunol 2002; 10: 63-72.
16. Chatenoud L, Jungers P, Descamps-Latscha B. Immunological considerations of the uremic and dialyzed patient. Kidney Int Suppl 1994; 44: S92-S96.
17. Yang W, Hussain S, Mi QS, Santamaria P, Delovitch TL. Perturbed homeostasis of peripheral T cells elicits decreased susceptibility to anti-CD3-induced apoptosis in prediabetic nonobese diabetic mice. J Immunol 2004; 173: 4407-4416.
18. Ochi H, Abraham M, Ishikawa H, et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med 2006; 12: 627-635.
19. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007; 56: 2103-2109.
20. Chatenoud L, Thervet E, Primo J, Bach J-F. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994; 91: 123-127.
21. Hayward AR, Shreiber M. Neonatal injection of CD3 antibody into nonobese diabetic mice reduces the incidence of insulitis and diabetes. J Immunol 1989; 143: 1555-1559.
22. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3: 123-132.
23. Chatenoud L, Bluestone JA. CD3-specific antibodies: portal to the treatment of autoimmunity. Nat Rev Immunol 2007; 7: 622-632.
24. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-1208.
25. Hirsch R, Bluestone JA, DeNenno L, Gress RE. Anti-CD3 F(ab')2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation 1990; 49: 1117-1123.
26. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23: 403-411.
27. Alegre ML, Peterson LJ, Xu D, et al. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation 1994; 57: 1537-1543.
28. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of T1DM. Diabetes 2005; 54: 1763-1769.
29. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset T1DM. N Engl J Med 2005; 352: 2598-2608.
30. Ilan Y, Zigmond E, Lalazar G, et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol 2009; 30: 167-177.